A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 7.7% in the morning session after the stock hit a new 52-week low amid persistent investor concerns over rising competition and the company's recent financial results.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) is an undervalued healthcare stock with strong profitability, financial health, and reasonable growth potential, making it a candidate for value investors.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Lantheus (NASDAQ:LNTH) and the best and worst performers in the medical devices & supplies - imaging, diagnostics industry.
Lantheus Holdings (NASDAQ:LNTH) presents an undervalued opportunity with strong profitability, financial health, and reasonable growth, making it a candidate for value investors.
Lantheus Holdings (LNTH) is an undervalued stock with strong profitability, financial health, and growth potential, trading below industry averages. A solid pick for value investors.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 22.2% in the afternoon session after the company reported weak first quarter 2025 results which included a significant miss on full-year EPS guidance and EPS falling short of Wall Street's estimates. Sales were flat, with a slight drop in PYLARIFY mostly offset by small gains in other parts of the business. Operating profit also fell. The real issue was the cut to full-year earnings, now seen at $6.60 to $6.70 per share, well below the $7.00 to $7.20 range it gave before. Overall, this was a softer quarter.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be announcing earnings results tomorrow before market open. Here’s what you need to know.
LANTHEUS HOLDINGS INC could be undervalued. NASDAQ:LNTH is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - imaging, diagnostics stocks fared in Q4, starting with Hologic (NASDAQ:HOLX).
Discover LANTHEUS HOLDINGS INC, an undervalued growth gem. NASDAQ:LNTH is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns,
and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including QuidelOrtho (NASDAQ:QDEL) and its peers.
